Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Somatic Cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    93 result(s) found for: Somatic Cell. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2019-002991-15 Sponsor Protocol Number: SOLTI-1804 Start Date*: 2019-11-04
    Sponsor Name:SOLTI
    Full Title: HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302
    Medical condition: Her2‑positive, unresectable and/or metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000109-10 Sponsor Protocol Number: UNITO-001/2020 Start Date*: 2020-09-30
    Sponsor Name:DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO
    Full Title: A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive fo...
    Medical condition: patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germ or somatic mutations in DNA damage repair genes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10045155 Tumor of pleura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001195-35 Sponsor Protocol Number: CA209-9LA Start Date*: 2017-09-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: Stage IV Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IE (Trial now transitioned) FR (Ongoing) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005584-24 Sponsor Protocol Number: PREOB-NU3 Start Date*: 2012-05-10
    Sponsor Name:Bone Therapeutics S.A.
    Full Title: A pivotal Phase IIb/III, multicentre, randomised, open, controlled study on the efficacy and safety of autologous osteoblastic cells (PREOB®) implantation in non-infected hypotrophic non-union frac...
    Medical condition: Non-infected hypotrophic non-union fractures of long bones
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10048617 Pseudarthrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003032-20 Sponsor Protocol Number: GOIRC-06-2016 Start Date*: 2017-03-01
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Nivolumab plus Stereotactic Body Radiotherapy (SBRT) in II and III line of Patients With Metastatic Renal Cell Carcinoma (mRCC).
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001462-15 Sponsor Protocol Number: MC-MSC.1/aGvHD Start Date*: 2020-09-24
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refrac...
    Medical condition: Steroid refractory Acute Graft versus host Disease
    Disease: Version SOC Term Classification Code Term Level
    27.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001983-36 Sponsor Protocol Number: AIO-TRK-0114 Start Date*: 2015-06-29
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Maintaining ERBB blockade in EGFR-mutated lung cancer (MARBLE) - A randomized, open-label, phase II study of maintaining pan-ERBB blockade following platinum-based induction chemotherapy in patient...
    Medical condition: Patients with stage IIIB or IV metastatic non-small-cell lung cancer with somatic EGFR mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000127-14 Sponsor Protocol Number: NCT-2017-0516 Start Date*: Information not available in EudraCT
    Sponsor Name:Heidelberg University Hospital
    Full Title: INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
    Medical condition: This trial investigates a novel combination treatment regimen using immune checkpoint inhibition and epigenetic therapy in children with relapsed/refractory/progressive high-risk solid tumors or CN...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) DE (Ongoing) NL (Ongoing) FR (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000076-28 Sponsor Protocol Number: BO29554 Start Date*: 2017-08-25
    Sponsor Name:Roche Farma S.A (Soc.Unipersonal) que realiza el ensayo
    Full Title: A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) HARBORIN...
    Medical condition: Advanced or metastatic Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Ongoing) BE (Ongoing) DE (Completed) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012949-33 Sponsor Protocol Number: Ty21a - ASC Start Date*: 2009-08-04
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Cross-reactive immunity elicited by oral and parenteral typhoid vaccines against non-typhoid Salmonellae
    Medical condition: Prophylaxis for healthy adult volunteers. Phase IV comparison study of typhoid fever vaccines.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004743-68 Sponsor Protocol Number: PUMA-NER-4201 Start Date*: 2014-05-06
    Sponsor Name:Puma Biotechnology, Inc.
    Full Title: A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
    Medical condition: Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002472-34 Sponsor Protocol Number: EGF109462 Start Date*: 2007-08-06
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer
    Medical condition: Patients with advanced or metatstatic Non-Small Cell Lung Cancer who have received one prior platinum containing chemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001484-27 Sponsor Protocol Number: NL67672.091.18 Start Date*: 2023-01-24
    Sponsor Name:radboudumc
    Full Title: B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissues Analysis 2
    Medical condition: Systemic Sclerosis Sjögren's Syndrome Cutaneous Lupus Erythematodus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001725-26 Sponsor Protocol Number: X-CGD-Version2 Start Date*: 2013-03-12
    Sponsor Name:Johann Wolfgang Goethe-University
    Full Title: A Phase I/II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector
    Medical condition: Chronic granulomatous disease (CGD) is a congenital immunodeficiency, in which neutrophil granulocytes and monocytes are not capable of producing reactive oxygen species and therefore are unable to...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10008906 Chronic granulomatous disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003103-22 Sponsor Protocol Number: BONSAI Start Date*: 2017-11-28
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Advanced or Metastatic Collecting ducts renal cell carcinoma
    Medical condition: Collecting Duct Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10073252 Carcinoma of the collecting ducts of Bellini LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004648-29 Sponsor Protocol Number: C05002 Start Date*: 2005-05-09
    Sponsor Name:Janssen Cilag International, N.V. (Sponsor in European Union)
    Full Title: A Multicenter, Open-label, Phase 2 Study of VELCADE (bortezomib) for Injection in Previously Treated Patients with Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloa...
    Medical condition: Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloalveolar Features
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001750-34 Sponsor Protocol Number: INCB39110-207 Start Date*: 2017-12-11
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
    Medical condition: Locally Advanced or Metastatic Non–Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002382-19 Sponsor Protocol Number: PDC-LUNG-101 Start Date*: 2019-06-13
    Sponsor Name:PDC*line Pharma SAS
    Full Title: An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, asso...
    Medical condition: Non-small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Ongoing) DE (Ongoing) NL (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000871-17 Sponsor Protocol Number: AGS-003-007 Start Date*: 2013-09-02
    Sponsor Name:Argos Therapeutics, Inc.
    Full Title: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
    Medical condition: Renal cell carcinoma (RCC)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004868-30 Sponsor Protocol Number: PNET5MB Start Date*: 2013-10-31
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (...
    Medical condition: Children with medulloblastoma. Medulloblastoma is a highly cellular malignant embryonal neoplasm.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Restarted) BE (Ongoing) IT (Ongoing) FR (Ongoing) FI (Ongoing) SE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) NO (Completed) CZ (Ongoing) NL (Ongoing) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 08:33:54 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA